EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Long‐term preservation of kidney function with SGLT ‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease

Gian Paolo Fadini iD, Enrico Longato, Mario Luca Morieri, Fabio Broglio, Gianluca Aimaretti, Giuseppina T Russo, Roberto Anichini, Mariangela Ghiani, Angelo Avogaro iD, Anna Solini iD, DARWIN‐Renal Study Investigators

Diabetes, Obesity and Metabolism · 2025-09 · 27 (9) · 5182-5191

DOI: 10.1111/dom.16569 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.07.2025. Verfasst von Gian Paolo Fadini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hypoglycemic Agents, Kidney. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Diabetes Society, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chronic kidney disease (CKD) is a prevalent and serious complication of type 2 diabetes (T2D). This study aims to evaluate kidney outcomes in a real‐world cohort of patients with T2D and CKD who received SGLT2 inhibitors (SGLT2i) or other glucose‐lowering medications (GLM). Materials and Methods This retrospective, multicentre study analysed data from patients aged 18–80 years with T2D and CKD, who initiated an SGLT2i or other GLM between 2015 and 2020. The primary outcome was the change in estimated glomerular filtration rate (eGFR) over time. Secondary outcomes included albuminuria changes and adverse kidney events. Propensity score matching was used to balance baseline characteristics between the two groups.

Results

After matching ( n = 2020/group), patients (100% T2D with CKD) had a mean age of 63 years, BMI 32 kg/m 2 , HbA1c 8.2%. New‐users of SGLT2i exhibited a slower decline in eGFR compared with new users of comparators (mean difference 1.43 mL/min/1.73 m 2 ; p = 0.048). Albuminuria improved significantly more in the SGLT2i group, with a greater likelihood of category improvement (hazard ratio [HR] 1.17; p = 0.007). SGLT2i initiation was associated with a lower incidence of kidney outcomes, including a ≥40% eGFR reduction (HR 0.63; p = 0.004). When the comparison was restricted to SGLT2i versus GLP‐1RA ( n = 1266/group), the eGFR slope was significantly better with SGLT2i (mean difference 0.62 mL/min/1.73 m 2 /year; p = 0.046).

Conclusions

In this large, real‐world cohort, initiation of SGLT2i was associated with a significantly slower decline in kidney function and improved albuminuria compared with other diabetes drugs, including GLP‐1RA. These findings support SGLT2i as the most effective T2D treatment to slow CKD progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesHypoglycemic AgentsKidneyRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultAlbuminuriaGlomerular Filtration RateRetrospective Studies

Stichwörter der Autor:innen

gliflozinobservationaloutcomesrenalretrospective

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Padova, Padova, Italy.
  • Veneto Institute of Molecular Medicine, Padova, Italy.
  • Department of Information Engineering, University of Padova, Padova, Italy.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
  • Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

ORCID-Profile: Gian Paolo Fadini, Angelo Avogaro, Anna Solini

Förderung

  • Italian Diabetes Society
  • AstraZeneca

Zitieren

APA

Fadini, G. P., Longato, E., Morieri, M. L., Broglio, F., Aimaretti, G., Russo, G. T., Anichini, R., Ghiani, M., Avogaro, A., Solini, A., & DARWIN‐Renal Study Investigators (2025). Long‐term preservation of kidney function with SGLT ‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 27(9), 5182-5191. https://doi.org/10.1111/dom.16569

Vancouver

Fadini GP, Longato E, Morieri ML, Broglio F, Aimaretti G, Russo GT, et al. Long‐term preservation of kidney function with SGLT ‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. 2025;27(9):5182-5191. doi:10.1111/dom.16569

BibTeX
@article{Fadini2025,
  author = {Fadini, Gian Paolo and Longato, Enrico and Morieri, Mario Luca and Broglio, Fabio and Aimaretti, Gianluca and Russo, Giuseppina T and Anichini, Roberto and Ghiani, Mariangela and Avogaro, Angelo and Solini, Anna and DARWIN‐Renal Study Investigators, DARWIN‐Renal Study Investigators},
  title = {Long‐term preservation of kidney function with SGLT ‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {9},
  pages = {5182--5191},
  doi = {10.1111/dom.16569}
}
Kostenlos starten →